Michael R. Megna - 15 Jul 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF ACCOUNTING OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
15 Jul 2024
Net transactions value
-$74,954
Form type
4
Filing time
04 Sep 2024, 20:57:36 UTC
Previous filing
08 Apr 2024
Next filing
08 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Award $7,512 +480 +2.2% $15.65 22,254 15 Jul 2024 Direct F1
transaction KNSA Class A Ordinary Share Options Exercise +6,490 +29% 28,744 01 Sep 2024 Direct F2
transaction KNSA Class A Ordinary Share Tax liability $73,669 -2,755 -9.6% $26.74 25,989 01 Sep 2024 Direct
transaction KNSA Class A Ordinary Share Options Exercise +775 +3% 26,764 02 Sep 2024 Direct F2
transaction KNSA Class A Ordinary Share Tax liability $8,797 -329 -1.2% $26.74 26,435 02 Sep 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Award $0 +9,450 $0.000000 9,450 01 Sep 2024 Class A Ordinary Share 9,450 Direct F2, F3
transaction KNSA Share Option Award $0 +18,900 $0.000000 18,900 01 Sep 2024 Class A Ordinary Share 18,900 $26.74 Direct F4
transaction KNSA Restricted Share Unit Options Exercise $0 -3,932 -33% $0.000000 7,865 01 Sep 2024 Class A Ordinary Share 3,932 Direct F2, F5
transaction KNSA Restricted Share Unit Options Exercise $0 -2,558 -25% $0.000000 7,672 01 Sep 2024 Class A Ordinary Share 2,558 Direct F2, F6
transaction KNSA Restricted Share Unit Options Exercise $0 -775 -50% $0.000000 774 02 Sep 2024 Class A Ordinary Share 775 Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2024 to July 15, 2024. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
F2 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F3 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.
F4 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024.
F5 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
F6 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.